Pan‐Cancer Survival Impact of Immune Checkpoint Inhibitors in a National Healthcare System
We demonstrated substantial increase in survival due to ICIs across a national health system, including in patient subgroups poorly represented on clinical trials.
Authors
- Lars G. Fritsche (ORCID: https://orcid.org/0000-0002-2110-1690)
- Sean R. Miller (ORCID: https://orcid.org/0000-0001-5059-2209)
- Silvia Crivelli (ORCID: https://orcid.org/0000-0003-1919-1890)
- Rafael Zamora‐Resendiz
- Steven G. Allen (ORCID: https://orcid.org/0000-0002-7402-4633)
- Michael D. Green (ORCID: https://orcid.org/0000-0003-4951-7118)
- Erkin Ötleş (ORCID: https://orcid.org/0000-0003-3169-6832)
- K. Nathan Sankar (ORCID: https://orcid.org/0000-0001-8636-8479)
- Benjamin H. McMahon (ORCID: https://orcid.org/0000-0002-8226-1276)
- Shinjae Yoo (ORCID: https://orcid.org/0000-0003-4378-6448)
- Garth William Strohbehn (ORCID: https://orcid.org/0000-0003-2973-3040)
- Donna M. Edwards (ORCID: https://orcid.org/0000-0001-7130-4755)
- Ralph Jiang (ORCID: https://orcid.org/0000-0001-9940-4109)
- Matthew J. Schipper (ORCID: https://orcid.org/0000-0001-6728-4720)
- Alex K. Bryant (ORCID: https://orcid.org/0000-0003-0194-8381)
- Xin Dai (ORCID: https://orcid.org/0000-0002-1097-5253)
- Nithya Ramnath
Institutions
- Cedars-Sinai Medical Center (US)
- Los Alamos National Laboratory (US)
- Lawrence Berkeley National Laboratory (US)
- Brookhaven National Laboratory (US)
- University of Michigan (US)
- VA Ann Arbor Healthcare System (US)
- VA Center for Clinical Management Research (US)
Publication Details
- Journal
- Cancer Medicine
- Published
- 2024-11-01
- DOI
- https://doi.org/10.1002/cam4.70379
- Citations
- 10
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 2.83
Funders
- U.S. Department of Veterans Affairs
- LUNGevity Foundation
- Melanoma Research Alliance
- National Cancer Institute